News

Adagene Launches New Trial for Colorectal Cancer Treatment

Adagene Launches New Trial for Colorectal Cancer Treatment

New Phase 2 Trial for ADG126 in Colorectal Cancer

Adagene Inc. has announced an investigator-initiated Phase 2 trial for its groundbreaking treatment, ADG126, targeting colorectal cancer. This trial will focus on patients diagnosed with stage II and III colorectal cancer, leveraging a combination approach that combines the immunotherapy agent ADG126 with KEYTRUDA. The aim is to enhance treatment efficacy before surgical intervention.

Trial Details

Set to start enrolling participants shortly, the trial is designed to evaluate the rate of major pathological response (MPR) — specifically targeting a threshold of 10% or less residual viable tumor present in the surgical specimens. Led by Dr. Yong Wei Peng from the National University Cancer Institute in Singapore, the trial will include an initial cohort of up to 20 patients to assess the primary endpoint, complemented by various secondary endpoints including complete pathological response and disease-free survival.

Innovative Approach to Cancer Treatment

Adagene’s ADG126 operates under the SAFEbody technology which utilizes precision masking to target only the tumor microenvironment while protecting healthy tissues from the adverse effects of conventional antibody therapies. This strategic design not only enhances safety but also promises a more effective therapeutic index against aggressive cancers.

Combination Therapy Insights

The inspiration behind this study lies in previous observations highlighting the complementary effects of ADG126 and pembrolizumab (KEYTRUDA) in advanced colorectal cancer patients. Peter Luo, CEO and President of R&D at Adagene, expressed optimism about this new approach. He emphasized the significant potential of combining CTLA-4-mediated T regulatory cell depletion with the rejuvenation of exhausted T cells through anti-PD-1 therapy to rekindle anti-tumor immunity in patients.

About Adagene Inc.

Adagene Inc. (NASDAQ: ADAG) is a pioneering entity in the biotechnology landscape, dedicated to transforming the sphere of antibody-based cancer immunotherapies. The company leverages computational biology in tandem with artificial intelligence to innovate and design antibodies that specifically cater to unmet medical needs globally. Through notable strategic partnerships, Adagene is leading the charge in cancer research.

Pipeline and Future Direction

Adagene’s proprietary Dynamic Precision Library (DPL) includes cutting-edge technologies like NEObody™, SAFEbody, and POWERbody™, which promise to innovate immunotherapy beyond traditional limits. This multi-faceted pipeline enables the company to explore various antibody-based therapeutic modalities. Beyond its leading program, ADG126, Adagene aims to push the boundaries of efficacy in cancer treatment while maintaining a focus on the safety profile of its therapies.

Navigating Challenges in Drug Development

The journey of drug development is not without its hurdles; Adagene faces challenges including demonstrating the efficacy and safety of their compounds in clinical settings. As they pursue regulatory approvals, the company is also focused on ensuring the protection of their intellectual property, which is crucial for their competitive edge. The landscape of clinical trials can be unpredictable, influenced by both external factors and the evolving nature of patient responses to therapy.

Investor Relations and Public Engagement

Maintaining strong communication with investors and interested stakeholders remains a priority. Adagene encourages inquiries and fosters transparency in their operations. For those seeking further information or wishing to stay connected, the company invites you to visit their investor relations website and follow their social media channels for the latest updates on clinical trials and advancements in their innovative therapies.

Frequently Asked Questions

What is the purpose of the Phase 2 trial for ADG126?

The trial aims to evaluate the major pathological response in colorectal cancer patients using ADG126 in conjunction with KEYTRUDA before surgical intervention.

Who is leading the trial?

The trial is being led by Dr. Yong Wei Peng, a Senior Consultant at the Department of Haematology-Oncology, National University Cancer Institute, Singapore.

What makes ADG126 unique?

ADG126 uses SAFEbody technology to specifically target tumor cells, reducing potential harm to surrounding healthy tissues while enhancing the efficacy of treatment.

When will patient enrollment begin?

Patient enrollment for the trial is expected to begin shortly, aiming for a major response assessment in a limited cohort.

How does Adagene support its commitment to innovation?

Adagene employs computational biology with AI in the design of antibodies, positioning itself at the forefront of cancer immunotherapy research.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 156

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 0

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
Scalefusion’s Platinum Win Sharpens Its Brand Story

Updated Category News Views 46

A Film Is Not a Balance Sheet A slick brand film cannot patch a leaky product, but it can make a complicated platform easier to remember. That is the sensible takeaway from Scalefusion’s Platinum Level win at the 2026 MarCom Awards for “One Platform. One Agent. We are Scalefusion.” The recognition is for creative execution, not commercial performance, and anybody...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 143

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 51

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 310

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 153

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading

Top 5 Most Recently Viewed Articles

Microvast Welcomes New CFO Pat Schultz to Drive Growth

Updated Category News Views 460

Microvast Holdings, Inc. Welcomes Pat Schultz as Chief Financial Officer Microvast Holdings, Inc. (NASDAQ: MVST), a prominent name in advanced battery technologies, has announced a significant change in its executive leadership team. The company is excited to introduce Carl T “Pat” Schultz as its new Chief Financial Officer. Pat Schultz's Impressive Background With...

Continue Reading
Cipla Faces Lanreotide Shortage: UBS Maintains Buy Rating

Updated Category News Views 536

UBS Adjusts Cipla's Price Target Amid Lanreotide Challenges Recent developments have placed Cipla Ltd. (CIPLA:IN) in the spotlight as UBS has decided to maintain its Buy rating on the company's shares, albeit with a notable revision. The price target has been decreased from INR2,060.00 to INR1,960.00, reflecting anticipated challenges due to a shortage of Lanreotide, an...

Continue Reading
Innovative Strategies at GovFin 2025 for Financial Progress

Updated Category News Views 197

GovFin 2025: Shaping the Future of Financial Reporting GovFin 2025 brings together leading minds to discuss the transformation of municipal bond issuance and the Financial Data Transparency Act (FDTA). With nine agencies preparing to finalize the first phase of FDTA rulemaking, expectations are high. Each agency will devise proposals for their own data collection...

Continue Reading
Broadway Licensing Unveils Festive Musical Holiday Showcase

Updated Category News Views 166

Broadway Licensing Introduces a Joyous Holiday Production Broadway Licensing, the prominent musical imprint of Broadway Licensing Global, is thrilled to share the launch of its latest holiday musical, Christmas in Connecticut. This enchanting show brings to life the beloved 1945 Warner Bros. Pictures film through its contemporary adaptation. Overview of the Musical's...

Continue Reading
Innovative Quick Connect Device Revolutionizes Electrical Installations

Updated Category News Views 198

Innovative Electrical Fixture Quick Connect Device In a world where electrical installations can be complicated and time-consuming, one inventor has sought to simplify this process significantly. The Electrical Fixture Quick Connect Device is designed to transform how lighting fixtures are connected to electrical networks. The vision behind this invention is...

Continue Reading